Genvor Announces Major Expansion Into The Health & Wellness Market Using Its AI-Accelerated BioCypher Platform For Consumer Peptide Development

Genvor, Inc., a biotechnology company using AI to create novel peptides for applications in both agriculture and human health, has announced its official entry into the human health and wellness sector. This marks a major strategic shift for the company as it expands beyond agriculture and moves into consumer-focused biological innovation. The company’s growth into this new space is built on its proprietary BioCypher platform, an AI-driven peptide generation engine supported by a library containing millions of designed peptides. This platform has already produced numerous agricultural lead candidates across more than a dozen pathogens and several areas of crop protection. 

Since the library also includes peptides engineered for health and wellness, Genvor is now using the same technology to identify and develop promising candidates that could become safe, effective, and commercially ready consumer wellness products. With the global market for peptide therapeutics and supplements rising rapidly and projected to reach multi-billion-dollar levels in the coming years, Genvor sees an opportunity to apply its scientific expertise to meet growing consumer demand. Industry forecasts indicate that the peptide supplements market alone will grow from around USD 4.1 billion in 2025 to approximately USD 11.2 billion by 2035. This growth is fueled by increased interest in muscle recovery, immune support, and bioavailable wellness products.

According to Chad Pawlak, the company’s chief executive officer, the BioCypher platform has already proven its strength across a wide range of agricultural pathogens and use cases. He explained that expanding into health and wellness allows Genvor to fully unlock the potential that has existed in its peptide library since the company’s formation. Pawlak added that advancing these candidates into consumer markets creates multiple revenue pathways from a single platform, helping the company innovate responsibly while delivering value to customers, partners, and investors.

The BioCypher platform uses computational biology and machine learning to design new peptides faster than traditional research methods. It supports candidates optimized not only for agricultural performance but also for human bioavailability. Genvor plans to use a dual-market commercialization approach: licensing agricultural technologies to major crop-science partners while using direct-to-consumer pathways, supported by strategic partnerships, to introduce peptide-based recovery and performance products to the health and wellness market.

The company is also in discussions with partners who bring expertise in performance, recovery, and wellness optimization. Its consumer health pipeline includes areas such as anti-aging, daily wellness, and targeted recovery, all powered by the same BioCypher-designed peptide structures used in its agricultural programs. As part of this expansion, Genvor has adjusted its leadership roles. 

George Stavrides, the company’s Executive Vice President of Business Development and Commercialization, will take on additional responsibility for advancing agricultural commercialization efforts. His focus will include building collaborations that generate revenue and strengthening licensing partnerships with leading agricultural companies. This ensures steady progress across Genvor’s agricultural initiatives, which currently span eight crop targets in both anti-pathogen and enhanced-nutrition applications.

Pawlak will dedicate more of his time to capital markets strategy and growing the company’s consumer peptide platform. His role will include partnership development, overseeing research collaborations, and aligning regulatory, commercial, and investor priorities as Genvor builds a presence in the human health and wellness space. Genvor is inviting new partners, investors, financial institutions, and collaborators to participate in this next phase of growth as it advances peptide-based solutions for both agriculture and consumer health.